Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Waning Effectiveness of the BNT162b2 Vaccine Against Infection in Adolescents

View ORCID ProfileOttavia Prunas, View ORCID ProfileDaniel M. Weinberger, View ORCID ProfileVirginia E. Pitzer, Sivan Gazit, Tal Patalon
doi: https://doi.org/10.1101/2022.01.04.22268776
Ottavia Prunas
1Department of Epidemiology of Microbial Diseases and Public Health Modeling Unit, Yale School of Public Health, Yale University; New Haven, CT USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ottavia Prunas
  • For correspondence: ottavia.prunastola@gmail.com
Daniel M. Weinberger
1Department of Epidemiology of Microbial Diseases and Public Health Modeling Unit, Yale School of Public Health, Yale University; New Haven, CT USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Daniel M. Weinberger
Virginia E. Pitzer
1Department of Epidemiology of Microbial Diseases and Public Health Modeling Unit, Yale School of Public Health, Yale University; New Haven, CT USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Virginia E. Pitzer
Sivan Gazit
2Kahn Sagol Maccabi (KSM) Research & Innovation Center, Maccabi Healthcare Services, Tel Aviv, Israel
3Maccabitech Institute for Research and Innovation, Maccabi Healthcare Services, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tal Patalon
2Kahn Sagol Maccabi (KSM) Research & Innovation Center, Maccabi Healthcare Services, Tel Aviv, Israel
3Maccabitech Institute for Research and Innovation, Maccabi Healthcare Services, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Background The short-term effectiveness of a two-dose regimen of the BioNTech/Pfizer mRNA BNT162b2 vaccine for adolescents has been demonstrated. However, little is known about the long-term effectiveness in this age group. It is known, though, that waning of vaccine-induced immunity against infection in adult populations is evident within a few months.

Methods Leveraging the centralized computerized database of Maccabi Healthcare Services (MHS), we conducted a matched case-control design for evaluating the association between time since vaccination and the incidence of infections, where two outcomes were evaluated separately: a documented SARS-CoV-2 infection (regardless of symptoms) and a symptomatic infection (COVID-19). Cases were defined as individuals aged 12 to 16 with a positive PCR test occurring between June 15 and December 8, 2021, when the Delta variant was dominant in Israel. Controls were adolescents who had not tested positive previously.

Results We estimated a peak vaccine effectiveness between 2 weeks and 3 months following receipt of the second dose, with 85% and 90% effectiveness against SARS-CoV-2 infection and COVID-19, respectively. However, in line with previous findings for adults, waning of vaccine effectiveness was evident in adolescents as well. Long-term protection conferred by the vaccine was reduced to 75-78% against infection and symptomatic infection, respectively, 3 to 5 months after the second dose, and waned to 58% against infection and 65% against COVID-19 after 5 months.

Conclusions Like adults, vaccine-induced protection against both SARS-CoV-2 infection and COVID-19 wanes with time, starting three months after inoculation and continuing for more than five months.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

Research reported in this publication was supported by NIAID of the National Institutes of Health under award number R01AI137093. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study protocol was approved by the Maccabi Healthcare Services' Institutional Review Board. Informed consent was waived by the IRB, as all identifying details of the participants were removed before computational analyses.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

According to the Israel Ministry of Health regulations, individual-level data cannot be shared openly. Specific requests for remote access to de-identified community-level data should be referred to KSM, Maccabi Healthcare Services Research and Innovation Center.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted January 05, 2022.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Waning Effectiveness of the BNT162b2 Vaccine Against Infection in Adolescents
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Waning Effectiveness of the BNT162b2 Vaccine Against Infection in Adolescents
Ottavia Prunas, Daniel M. Weinberger, Virginia E. Pitzer, Sivan Gazit, Tal Patalon
medRxiv 2022.01.04.22268776; doi: https://doi.org/10.1101/2022.01.04.22268776
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Waning Effectiveness of the BNT162b2 Vaccine Against Infection in Adolescents
Ottavia Prunas, Daniel M. Weinberger, Virginia E. Pitzer, Sivan Gazit, Tal Patalon
medRxiv 2022.01.04.22268776; doi: https://doi.org/10.1101/2022.01.04.22268776

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Epidemiology
Subject Areas
All Articles
  • Addiction Medicine (243)
  • Allergy and Immunology (525)
  • Anesthesia (125)
  • Cardiovascular Medicine (1434)
  • Dentistry and Oral Medicine (220)
  • Dermatology (158)
  • Emergency Medicine (292)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (589)
  • Epidemiology (10330)
  • Forensic Medicine (6)
  • Gastroenterology (533)
  • Genetic and Genomic Medicine (2653)
  • Geriatric Medicine (255)
  • Health Economics (499)
  • Health Informatics (1744)
  • Health Policy (791)
  • Health Systems and Quality Improvement (681)
  • Hematology (269)
  • HIV/AIDS (570)
  • Infectious Diseases (except HIV/AIDS) (12119)
  • Intensive Care and Critical Care Medicine (650)
  • Medical Education (276)
  • Medical Ethics (83)
  • Nephrology (291)
  • Neurology (2483)
  • Nursing (145)
  • Nutrition (381)
  • Obstetrics and Gynecology (497)
  • Occupational and Environmental Health (569)
  • Oncology (1333)
  • Ophthalmology (403)
  • Orthopedics (152)
  • Otolaryngology (239)
  • Pain Medicine (172)
  • Palliative Medicine (51)
  • Pathology (345)
  • Pediatrics (786)
  • Pharmacology and Therapeutics (334)
  • Primary Care Research (297)
  • Psychiatry and Clinical Psychology (2419)
  • Public and Global Health (5031)
  • Radiology and Imaging (901)
  • Rehabilitation Medicine and Physical Therapy (536)
  • Respiratory Medicine (688)
  • Rheumatology (309)
  • Sexual and Reproductive Health (257)
  • Sports Medicine (246)
  • Surgery (300)
  • Toxicology (45)
  • Transplantation (141)
  • Urology (108)